OptimizeRx Co. (NASDAQ:OPRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of OptimizeRx Co. (NASDAQ:OPRX) have been given an average recommendation of “Moderate Buy” by the nine analysts that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $9.06.

Several equities research analysts recently commented on OPRX shares. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $6.00 price objective (down from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Stephens started coverage on shares of OptimizeRx in a research report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price objective on the stock. Lake Street Capital reaffirmed a “buy” rating and issued a $11.00 price objective on shares of OptimizeRx in a research report on Tuesday, December 24th. B. Riley raised shares of OptimizeRx to a “strong-buy” rating in a research report on Wednesday, March 12th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 price objective on shares of OptimizeRx in a research report on Thursday, February 6th.

OptimizeRx Price Performance

Shares of OPRX stock opened at $9.02 on Wednesday. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $14.13. The firm has a market capitalization of $166.16 million, a price-to-earnings ratio of -6.78 and a beta of 1.31. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. The firm has a fifty day moving average of $5.64 and a 200-day moving average of $5.90.

Institutional Investors Weigh In On OptimizeRx

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Whetstone Capital Advisors LLC bought a new stake in OptimizeRx during the 4th quarter worth about $6,563,000. Royce & Associates LP bought a new stake in OptimizeRx during the 4th quarter worth about $5,198,000. Kennedy Capital Management LLC increased its stake in shares of OptimizeRx by 57.8% during the 4th quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company’s stock worth $2,887,000 after purchasing an additional 217,676 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of OptimizeRx by 9.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 444,167 shares of the company’s stock worth $2,159,000 after purchasing an additional 39,740 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of OptimizeRx by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 400,621 shares of the company’s stock worth $1,948,000 after purchasing an additional 4,821 shares during the last quarter. 76.47% of the stock is owned by institutional investors.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.